VYTRUS BIOTECH EO -01 (V5P) - Total Liabilities
Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore V5P cash generation efficiency to assess how effectively this company generates cash.
VYTRUS BIOTECH EO -01 - Total Liabilities Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are VYTRUS BIOTECH EO -01's assets to evaluate the company's liquid asset resilience ratio.
VYTRUS BIOTECH EO -01 Competitors by Total Liabilities
The table below lists competitors of VYTRUS BIOTECH EO -01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Evertop Wire Cable Corp
TW:1616
|
Taiwan | NT$2.06 Billion |
|
Interactive Digital Technologies
TWO:6486
|
Taiwan | NT$1.53 Billion |
|
Cheryong Industrial Co.Ltd
KQ:147830
|
Korea | ₩13.83 Billion |
|
Salasar Techno Engineering Limited
NSE:SALASAR
|
India | Rs10.35 Billion |
|
Corpovael S.A.B. de C.V
MX:CADUA
|
Mexico | MX$6.43 Billion |
|
Generation Mining Ltd
TO:GENM
|
Canada | CA$69.62 Million |
|
Fate Therapeutics Inc
NASDAQ:FATE
|
USA | $109.61 Million |
|
The Pinkfong Company
KQ:403850
|
Korea | ₩19.70 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down VYTRUS BIOTECH EO -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see V5P market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VYTRUS BIOTECH EO -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual total liabilities of VYTRUS BIOTECH EO -01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.35 Million ≈ $5.09 Million |
+13.44% |
| 2024-12-31 | €3.84 Million ≈ $4.49 Million |
-4.57% |
| 2023-12-31 | €4.02 Million ≈ $4.70 Million |
+23.76% |
| 2022-12-31 | €3.25 Million ≈ $3.80 Million |
+10.85% |
| 2021-12-31 | €2.93 Million ≈ $3.43 Million |
-- |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more